On the public citation graph
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
0 signed · 3198 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
1 of the 199 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-28): 10.1002/lt.20701 (notice 2026-05-01).
Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →no DOI in the source recordopenalex-snapshot
Staphylococcal nasal carriage of health care workers.
inferredcites →https://doi.org/10.1001/2012.jama.11975openalex-snapshot
Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver Resection
inferredcites →https://doi.org/10.1001/archinte.150.5.1051openalex-snapshot
Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers
inferredcites →https://doi.org/10.1001/archinte.1990.00390170087019openalex-snapshot
Hepatitis B–Related Sequelae
inferredcites →https://doi.org/10.1001/jama.1985.03350360066020openalex-snapshot
Perinatal Hepatitis B Virus Transmission in the United States
inferredcites →https://doi.org/10.1001/jama.1986.03370070088032openalex-snapshot
Transmission of Hepatitis B With Resultant Restriction of Surgical Practice
inferredcites →https://doi.org/10.1001/jama.2011.351openalex-snapshot
Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1
inferredcites →https://doi.org/10.1001/jama.2013.276701openalex-snapshot
Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan
inferredcites →https://doi.org/10.1001/jama.281.21.2029openalex-snapshot
Users' Guides to the Medical Literature
inferredcites →https://doi.org/10.1001/jama.295.1.65openalex-snapshot
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
inferredcites →https://doi.org/10.1002/(sici)1096-9071(199908)58:4<332::aid-jmv3>3.0.co;2-qopenalex-snapshot
Low level wild-type and pre-core mutant hepatitis B viruses and hbeAg negative reactivation of chronic hepatitis B
inferredcites →https://doi.org/10.1002/(sici)1096-9071(199912)59:4<415::aid-jmv1>3.0.co;2-mopenalex-snapshot
Hepatitis B virus core promoter mutations in children with multiple anti-HBe/HBeAg reactivations result in enhanced promoter activity
inferredcites →https://doi.org/10.1002/1096-9071(200012)62:4<450::aid-jmv9>3.0.co;2-yopenalex-snapshot
Serological pattern ?anti-HBc alone?: Report on a workshop
inferredcites →https://doi.org/10.1002/14651858.cd006002.pub2openalex-snapshot
Interferon alpha for chronic hepatitis D
inferredcites →https://doi.org/10.1002/art.20401openalex-snapshot
Short‐term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus–related polyarteritis nodosa
inferredcites →https://doi.org/10.1002/art.27240openalex-snapshot
Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database
inferredcites →https://doi.org/10.1002/bjs.6731openalex-snapshot
Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis
inferredcites →https://doi.org/10.1002/cncr.20427openalex-snapshot
Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.
inferredcites →https://doi.org/10.1002/hep.1840070106openalex-snapshot
Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients
inferredcites →https://doi.org/10.1002/hep.1840070215openalex-snapshot
Long-term follow-up study of asymptomatic hbsag-positive voluntary blood donors in austria: A clinical and histologic evaluation of 242 cases
inferredcites →https://doi.org/10.1002/hep.1840080310openalex-snapshot
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
inferredcites →https://doi.org/10.1002/hep.1840080411openalex-snapshot
Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs
inferredcites →https://doi.org/10.1002/hep.1840360617openalex-snapshot
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
inferredcites →https://doi.org/10.1002/hep.20240openalex-snapshot
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects
inferredcites →https://doi.org/10.1002/hep.20748openalex-snapshot
Functional Analysis of Hepatitis B Virus Reactivating in Hepatitis B Surface Antigen-Negative Individuals *
inferredcites →https://doi.org/10.1002/hep.20944openalex-snapshot
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients†‡
inferredcites →https://doi.org/10.1002/hep.20956openalex-snapshot
Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005
inferredcites →https://doi.org/10.1002/hep.21077openalex-snapshot
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study
inferredcites →https://doi.org/10.1002/hep.21325openalex-snapshot
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up
inferredcites →https://doi.org/10.1002/hep.21486openalex-snapshot
A randomized controlled trial of lamivudine to treat acute hepatitis B
inferredcites →https://doi.org/10.1002/hep.21529openalex-snapshot
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma
inferredcites →https://doi.org/10.1002/hep.21572openalex-snapshot
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
inferredcites →https://doi.org/10.1002/hep.21585openalex-snapshot
Hepatitis B viral factors in HBeAg‐Negative carriers with persistently normal serum alanine aminotransferase levels†
inferredcites →https://doi.org/10.1002/hep.21723openalex-snapshot
Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis† ‡ §
inferredcites →https://doi.org/10.1002/hep.21724openalex-snapshot
Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase†
inferredcites →https://doi.org/10.1002/hep.21784openalex-snapshot
Why we should routinely screen Asian American adults for hepatitis B
inferredcites →https://doi.org/10.1002/hep.22065openalex-snapshot
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.22075openalex-snapshot
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
inferredcites →https://doi.org/10.1002/hep.22106openalex-snapshot
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
inferredcites →https://doi.org/10.1002/hep.22250openalex-snapshot
Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.22414openalex-snapshot
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.22524openalex-snapshot
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis
inferredcites →https://doi.org/10.1002/hep.22744openalex-snapshot
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #
inferredcites →https://doi.org/10.1002/hep.22841openalex-snapshot
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
inferredcites →https://doi.org/10.1002/hep.22882openalex-snapshot
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection #
inferredcites →https://doi.org/10.1002/hep.22883openalex-snapshot
Hepatitis B and human immunodeficiency virus coinfection #
inferredcites →https://doi.org/10.1002/hep.22951openalex-snapshot
Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference #
inferredcites →https://doi.org/10.1002/hep.23323openalex-snapshot
Lamivudine Maintenance Beyond One Year After Hbeag Seroconversion Is A Major Factor for Sustained Virologic Response in Hbeag-Positive Chronic Hepatitis B
inferredcites →https://doi.org/10.1002/hep.23346openalex-snapshot
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function†
inferredcites →https://doi.org/10.1002/hep.23561openalex-snapshot
Institute of Medicine Recommendations for the Prevention and Control of Hepatitis B and C
inferredcites →https://doi.org/10.1002/hep.23785openalex-snapshot
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡
inferredcites →https://doi.org/10.1002/hep.23844openalex-snapshot
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen–Positive Chronic Hepatitis B Using on-Treatment Hepatitis B Surface Antigen Decline
inferredcites →https://doi.org/10.1002/hep.23886openalex-snapshot
Impact of Hepatitis B Virus Surface Protein Mutations on the Diagnosis of Occult Hepatitis B Virus Infection
inferredcites →https://doi.org/10.1002/hep.23905openalex-snapshot
Kinetics of Hepatitis B Surface Antigen Decline During 3 Years of Telbivudine Treatment in Hepatitis B e Antigen–Positive Patients
inferredcites →https://doi.org/10.1002/hep.23952openalex-snapshot
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
inferredcites →https://doi.org/10.1002/hep.24109openalex-snapshot
Tenofovir Improves the Outcome in Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-On-Chronic Liver Failure §Δ
inferredcites →https://doi.org/10.1002/hep.24121openalex-snapshot
Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan) σ
inferredcites →https://doi.org/10.1002/hep.24136openalex-snapshot
Further Analysis Is Required to Identify an Early Stopping Rule for Peginterferon Therapy That Is Valid for All Hepatitis B e Antigen–Positive Patients *†#
inferredcites →https://doi.org/10.1002/hep.24199openalex-snapshot
Management of Hepatocellular Carcinoma: An Update Δσ
inferredcites →https://doi.org/10.1002/hep.24221openalex-snapshot
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
inferredcites →https://doi.org/10.1002/hep.24406openalex-snapshot
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
inferredcites →https://doi.org/10.1002/hep.24529openalex-snapshot
Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy
inferredcites →https://doi.org/10.1002/hep.24551openalex-snapshot
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma
inferredcites →https://doi.org/10.1002/hep.24555openalex-snapshot
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
inferredcites →https://doi.org/10.1002/hep.24758openalex-snapshot
Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation
inferredcites →https://doi.org/10.1002/hep.25636openalex-snapshot
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.25749openalex-snapshot
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.25818openalex-snapshot
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.25875openalex-snapshot
Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies
inferredcites →https://doi.org/10.1002/hep.26041openalex-snapshot
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads
inferredcites →https://doi.org/10.1002/hep.26121openalex-snapshot
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
inferredcites →https://doi.org/10.1002/hep.26180openalex-snapshot
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
inferredcites →https://doi.org/10.1002/hep.26266openalex-snapshot
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
inferredcites →https://doi.org/10.1002/hep.26277openalex-snapshot
Efficacy of Tenofovir Disoproxil Fumarate At 240 Weeks in Patients With Chronic Hepatitis B With High Baseline Viral Load
inferredcites →https://doi.org/10.1002/hep.26301openalex-snapshot
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
inferredcites →https://doi.org/10.1002/hep.26376openalex-snapshot
Reduction of Hepatitis B Surface Antigen Levels And Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients Receiving 10 Years of Nucleoside Analogue Therapy
inferredcites →https://doi.org/10.1002/hep.26385openalex-snapshot
Prediction Models of Long-Term Cirrhosis and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: Risk Scores Integrating Host and Virus Profiles
inferredcites →https://doi.org/10.1002/hep.26436openalex-snapshot
Response-Guided Peginterferon Therapy in Hepatitis B E Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
inferredcites →https://doi.org/10.1002/hep.26549openalex-snapshot
Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients
inferredcites →https://doi.org/10.1002/hep.26635openalex-snapshot
Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults
inferredcites →https://doi.org/10.1002/hep.26718openalex-snapshot
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
inferredcites →https://doi.org/10.1002/hep.26885openalex-snapshot
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study
inferredcites →https://doi.org/10.1002/hep.26910openalex-snapshot
Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy
inferredcites →https://doi.org/10.1002/hep.27034openalex-snapshot
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
inferredcites →https://doi.org/10.1002/hep.27382openalex-snapshot
Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta‐analysis
inferredcites →https://doi.org/10.1002/hep.27389openalex-snapshot
Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test
inferredcites →https://doi.org/10.1002/hep.27586openalex-snapshot
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
inferredcites →https://doi.org/10.1002/hep.27837openalex-snapshot
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus
inferredcites →https://doi.org/10.1002/hep.510240601openalex-snapshot
Prophylaxis in Liver Transplant Recipients Using A Fixed Dosing Schedule of Hepatitis B Immunoglobulin
inferredcites →https://doi.org/10.1002/hep.510270526openalex-snapshot
Persistent viremia after recovery from self-limited acute hepatitis B
inferredcites →https://doi.org/10.1002/hep.510290447openalex-snapshot
Influence of Human Immunodeficiency Virus Infection on Chronic Hepatitis B in Homosexual Men
inferredcites →https://doi.org/10.1002/ijc.25321openalex-snapshot
Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta‐analysis
inferredcites →https://doi.org/10.1002/ijc.25516openalex-snapshot
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
inferredcites →https://doi.org/10.1002/j.1536-4801.2005.tb00953.xopenalex-snapshot
Chronic Hepatitis B Infection: Long Term Comparison of Children Receiving Interferon Alpha and Untreated Controls
inferredcites →https://doi.org/10.1002/jmv.10291openalex-snapshot
Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses
inferredcites →https://doi.org/10.1002/jmv.10534openalex-snapshot
Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers
inferredcites →https://doi.org/10.1002/jmv.1890180402openalex-snapshot
Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan
inferredcites →https://doi.org/10.1002/jmv.1890210205openalex-snapshot
Dynamics and impact of perinatal transmission of hepatitis B virus in North India
inferredcites →https://doi.org/10.1002/jmv.20320openalex-snapshot
Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan
inferredcites →https://doi.org/10.1002/jmv.21523openalex-snapshot
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: Clinical considerations and disease burden
inferredcites →https://doi.org/10.1002/jmv.22017openalex-snapshot
Prevalence, risk factors and virological profile of chronic hepatitis b virus infection in pregnant women in India
inferredcites →https://doi.org/10.1002/lt.20402openalex-snapshot
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence
inferredcites →https://doi.org/10.1002/lt.20701openalex-snapshot
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis
inferredcites →https://doi.org/10.1002/lt.20981openalex-snapshot
Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B
inferredcites →https://doi.org/10.1002/lt.22354openalex-snapshot
Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review
inferredcites →https://doi.org/10.1002/lt.23600openalex-snapshot
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen–positive liver transplant candidates
inferredcites →https://doi.org/10.1002/lt.23628openalex-snapshot
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation
inferredcites →https://doi.org/10.1002/lt.23692openalex-snapshot
Living related liver transplantation for hepatitis B–related liver disease without hepatitis B immune globulin prophylaxis
inferredcites →https://doi.org/10.1002/phar.1188openalex-snapshot
Comparative Efficacy of Oral Nucleoside or Nucleotide Analog Monotherapy Used in Chronic Hepatitis B : A Mixed‐Treatment Comparison Meta‐analysis
inferredcites →https://doi.org/10.1006/scbi.2000.0321openalex-snapshot
Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)
inferredcites →https://doi.org/10.1007/bf01650760openalex-snapshot
The aetiology of acute hepatitis in Taiwan: Acute hepatitis superimposed on HBsAg carrier state as the main aetiology of acute hepatitis in areas with high HBsAg carrier rate
inferredcites →https://doi.org/10.1007/s001040051070openalex-snapshot
Übertragung von HBV, HCV und HIV durch infektiöses medizinisches Personal – eine Übersichtsdarstellung
inferredcites →https://doi.org/10.1007/s00268-014-2586-zopenalex-snapshot
Antiviral Therapy Decreases Recurrence of Hepatitis B Virus‐related Hepatocellular Carcinoma after Curative Resection: A Meta‐analysis
inferredcites →https://doi.org/10.1007/s00277-011-1241-0openalex-snapshot
Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis
inferredcites →https://doi.org/10.1007/s00535-004-1400-3openalex-snapshot
Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001
inferredcites →https://doi.org/10.1007/s00535-010-0304-7openalex-snapshot
Natural history of hepatitis B virus infection: pediatric perspective
inferredcites →https://doi.org/10.1007/s00535-012-0561-8openalex-snapshot
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection
inferredcites →https://doi.org/10.1007/s00535-013-0761-xopenalex-snapshot
Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin
inferredcites →https://doi.org/10.1007/s00535-013-0840-zopenalex-snapshot
Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy
inferredcites →https://doi.org/10.1007/s10067-010-1523-2openalex-snapshot
Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action
inferredcites →https://doi.org/10.1007/s10238-011-0160-7openalex-snapshot
Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure
inferredcites →https://doi.org/10.1007/s10549-013-2681-0openalex-snapshot
Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature
inferredcites →https://doi.org/10.1007/s10620-006-3175-2openalex-snapshot
Differentiating Acute Hepatitis B from the First Episode of Symptomatic Exacerbation of Chronic Hepatitis B
inferredcites →https://doi.org/10.1007/s10620-009-1060-5openalex-snapshot
The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B
inferredcites →https://doi.org/10.1007/s10620-009-1083-yopenalex-snapshot
Clinical Significance of Genotypes and Precore/Basal Core Promoter Mutations in HBV Related Chronic Liver Disease Patients in North India
inferredcites →https://doi.org/10.1007/s10620-012-2187-3openalex-snapshot
Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series
inferredcites →https://doi.org/10.1007/s10620-012-2402-2openalex-snapshot
Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders
inferredcites →https://doi.org/10.1007/s10620-014-3486-7openalex-snapshot
Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
inferredcites →https://doi.org/10.1007/s11894-001-0044-1openalex-snapshot
Extrahepatic manifestations of chronic viral hepatitis
inferredcites →https://doi.org/10.1007/s11901-008-0015-1openalex-snapshot
Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis
inferredcites →https://doi.org/10.1007/s11908-012-0307-zopenalex-snapshot
Treatment Options for Hepatitis Delta Virus Infection
inferredcites →https://doi.org/10.1007/s11926-005-0036-5openalex-snapshot
Epidemiology of systemic vasculitis
inferredcites →https://doi.org/10.1007/s12072-007-9022-5openalex-snapshot
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
inferredcites →https://doi.org/10.1007/s12072-008-9046-5openalex-snapshot
Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B
inferredcites →https://doi.org/10.1007/s12072-009-9148-8openalex-snapshot
Liver transplantation for acute-on-chronic liver failure
inferredcites →https://doi.org/10.1007/s12072-010-9165-7openalex-snapshot
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
inferredcites →https://doi.org/10.1007/s12072-012-9343-xopenalex-snapshot
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
inferredcites →https://doi.org/10.1007/s12072-012-9365-4openalex-snapshot
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
inferredcites →https://doi.org/10.1007/s12072-012-9380-5openalex-snapshot
Analysis of discordance between transient elastography and liver biopsy for assessing liver fibrosis in chronic hepatitis B virus infection
inferredcites →https://doi.org/10.1007/s12072-013-9439-yopenalex-snapshot
Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B
inferredcites →https://doi.org/10.1007/s12072-014-9562-4openalex-snapshot
Community-based hepatitis B screening: what works?
inferredcites →https://doi.org/10.1016/0002-9343(74)90020-5openalex-snapshot
Arthritis in acute hepatitis and chronic active hepatitis
inferredcites →https://doi.org/10.1016/0016-5085(80)90378-9openalex-snapshot
Chronic asymptomatic HBsAg carriers: Histologic abnormalities and diagnostic and prognostic value of serologic markers of the HBV
inferredcites →https://doi.org/10.1016/0016-5085(85)90566-9openalex-snapshot
Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis
inferredcites →https://doi.org/10.1016/0016-5085(87)90613-5openalex-snapshot
Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
inferredcites →https://doi.org/10.1016/0016-5085(87)90614-7openalex-snapshot
Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults
inferredcites →https://doi.org/10.1016/0016-5085(87)90641-xopenalex-snapshot
Reactivation of chronic hepatitis B virus infection
inferredcites →https://doi.org/10.1016/0016-5085(90)90972-4openalex-snapshot
Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood
inferredcites →https://doi.org/10.1016/0016-5085(91)90599-gopenalex-snapshot
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
inferredcites →https://doi.org/10.1016/0140-6736(90)91735-sopenalex-snapshot
Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs in two Chinese families
inferredcites →https://doi.org/10.1016/0168-8278(90)90069-4openalex-snapshot
Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection
inferredcites →https://doi.org/10.1016/j.amjmed.2003.12.040openalex-snapshot
Natural history of hepatitis b e antigen to antibody seroconversion in patients with normal serum aminotransferase levels
inferredcites →https://doi.org/10.1016/j.antiviral.2012.12.008openalex-snapshot
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes
inferredcites →https://doi.org/10.1016/j.antiviral.2013.06.007openalex-snapshot
β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity
inferredcites →https://doi.org/10.1016/j.bbrc.2013.12.052openalex-snapshot
Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP
inferredcites →https://doi.org/10.1016/j.cgh.2007.01.005openalex-snapshot
Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome
inferredcites →https://doi.org/10.1016/j.cgh.2007.06.015openalex-snapshot
Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection
inferredcites →https://doi.org/10.1016/j.cgh.2010.02.023openalex-snapshot
Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B
inferredcites →https://doi.org/10.1016/j.cgh.2010.12.027openalex-snapshot
A Model to Determine 3-Month Mortality Risk in Patients With Acute-on-Chronic Hepatitis B Liver Failure
inferredcites →https://doi.org/10.1016/j.cgh.2011.08.029openalex-snapshot
Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection
inferredcites →https://doi.org/10.1016/j.cgh.2013.04.036openalex-snapshot
Management of Hepatitis B: Our Practice and How It Relates to the Guidelines
inferredcites →https://doi.org/10.1016/j.cgh.2013.11.038openalex-snapshot
Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis and Systematic Review
inferredcites →https://doi.org/10.1016/j.cld.2005.10.005openalex-snapshot
Hepatitis B and C in Children: Current Treatment and Future Strategies
inferredcites →https://doi.org/10.1016/j.cld.2013.09.015openalex-snapshot
The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease
inferredcites →https://doi.org/10.1016/j.clinre.2013.10.012openalex-snapshot
Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg-negative acute-on-chronic liver failure
inferredcites →https://doi.org/10.1016/j.dld.2006.12.017openalex-snapshot
Prophylaxis and treatment of hepatitis B in immunocompromised patients
inferredcites →https://doi.org/10.1016/j.dld.2011.06.013openalex-snapshot
Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis
inferredcites →https://doi.org/10.1016/j.dld.2012.09.021openalex-snapshot
Occult hepatitis B virus and the risk for chronic liver disease: A meta-analysis
inferredcites →https://doi.org/10.1016/j.dld.2012.12.013openalex-snapshot
Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.ejso.2012.04.010openalex-snapshot
High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: A prospective cohort study
inferredcites →https://doi.org/10.1016/j.gastro.2005.05.053openalex-snapshot
A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis B
inferredcites →https://doi.org/10.1016/j.gtc.2006.03.002openalex-snapshot
Hepatitis B: The Pathway to Recovery Through Treatment
inferredcites →https://doi.org/10.1016/j.gtc.2006.10.002openalex-snapshot
Hepatitis B: The Pathway to Recovery Through Treatment
inferredcites →https://doi.org/10.1016/j.ijporl.2014.11.015openalex-snapshot
Histopathological evaluation of Ankaferd blood stopper use in the rabbit septoplasty model
inferredcites →https://doi.org/10.1016/j.jcv.2006.01.003openalex-snapshot
Fully automated quantitation of Hepatitis B virus (HBV) DNA in human plasma by the COBAS® AmpliPrep/COBAS® TaqMan® System☆, ☆☆
inferredcites →https://doi.org/10.1016/j.jcv.2009.07.005openalex-snapshot
Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.jcv.2009.09.027openalex-snapshot
Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine
inferredcites →https://doi.org/10.1016/j.jcv.2011.07.014openalex-snapshot
HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance
inferredcites →https://doi.org/10.1016/j.jcv.2012.01.024openalex-snapshot
Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.jcv.2013.08.010openalex-snapshot
Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
inferredcites →https://doi.org/10.1016/j.jcv.2014.06.005openalex-snapshot
Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus
inferredcites →https://doi.org/10.1016/j.jfma.2013.05.011openalex-snapshot
Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
inferredcites →https://doi.org/10.1016/j.jhep.2004.10.019openalex-snapshot
Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis
inferredcites →https://doi.org/10.1016/j.jhep.2004.11.037openalex-snapshot
Occult hepatitis B virus infection in a North American community-based population
inferredcites →https://doi.org/10.1016/j.jhep.2005.03.018openalex-snapshot
Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: A longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline
inferredcites →https://doi.org/10.1016/j.jhep.2006.05.013openalex-snapshot
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
inferredcites →https://doi.org/10.1016/j.jhep.2007.07.022openalex-snapshot
The clinical significance of persistently normal ALT in chronic hepatitis B infection
inferredcites →https://doi.org/10.1016/j.jhep.2008.03.028openalex-snapshot
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection
inferredcites →https://doi.org/10.1016/j.jhep.2008.07.023openalex-snapshot
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.jhep.2008.07.039openalex-snapshot
Exceeding the limits of liver histology markers
inferredcites →https://doi.org/10.1016/j.jhep.2008.10.001openalex-snapshot
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.jhep.2008.10.014openalex-snapshot
Liver biopsy: The best, not the gold standard
inferredcites →https://doi.org/10.1016/j.jhep.2008.12.019openalex-snapshot
Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.jhep.2009.04.003openalex-snapshot
Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia
inferredcites →https://doi.org/10.1016/j.jhep.2009.05.020openalex-snapshot
Transfusion-transmitted hepatitis B virus infection
inferredcites →https://doi.org/10.1016/j.jhep.2009.06.011openalex-snapshot
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B
inferredcites →https://doi.org/10.1016/j.jhep.2009.07.009openalex-snapshot
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/j.jhep.2009.10.036openalex-snapshot
Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D
showing the first 200 of 659 · page through all 659
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.12688/openreseurope.20378.1zenodo-depositor-declared
Immunomodulatory effect of Moringa oleifera and Phyllanthus niruri extracts on anti-HBV cytokine production by human peripheral blood mononuclear cells
inferred← citeshttps://doi.org/10.12688/openreseurope.20378.2zenodo-depositor-declared
Immunomodulatory effect of Moringa oleifera and Phyllanthus niruri extracts on anti-HBV cytokine production by human peripheral blood mononuclear cells
inferred← citeshttps://doi.org/10.12688/openreseurope.20378.3zenodo-depositor-declared
Immunomodulatory effect of Moringa oleifera and Phyllanthus niruri extracts on anti-HBV cytokine production by human peripheral blood mononuclear cells
inferred← citeshttps://doi.org/10.2139/ssrn.3736190openalex-extracted
A Cautionary Note to Hepatitis B e ANTIGEN (HBeAg)-Negative Status of Pregnant Women
inferred← citeshttps://doi.org/10.2139/ssrn.3759709openalex-extracted
Substantial Gaps in Evaluation and Treatment of Hepatitis B Patients in the US: A Nationwide Study of 14,693 Patients
inferred← citeshttps://doi.org/10.2139/ssrn.3800861openalex-extracted
Safety and Efficacy of Antiviral Therapy for Chronic Hepatitis B Throughout Entire Pregnancy
inferred← citeshttps://doi.org/10.2139/ssrn.4472080openalex-extracted
Hepatocellular Carcinoma Risk in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B Living in Europe: An International Multicenter Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1001/jamainternmed.2018.8342openalex-snapshot
Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.19407openalex-snapshot
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.7018openalex-snapshot
Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.35777openalex-snapshot
WHO 2024 Hepatitis B Guidelines and Treatment-Eligible Rate Among Treatment-Naive Patients
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.42744openalex-snapshot
Hepatitis B Virus Treatment Gaps in the US
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4039openalex-snapshot
Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4070openalex-snapshot
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/14651858.cd014610openalex-snapshot
Thymosin-ɑ1 for people with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/14651858.cd014610.pub2openalex-snapshot
Thymosin-ɑ1 for people with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/1878-0261.13041openalex-snapshot
Characterization of fragment sizes, copy number aberrations and 4‐mer end motifs in cell‐free DNA of hepatocellular carcinoma for enhanced liquid biopsy‐based cancer detection
inferred← citeshttps://doi.org/10.1002/9781119533481.ch26openalex-snapshot
Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes
inferred← citeshttps://doi.org/10.1002/9781119533481.ch31openalex-snapshot
The stopping rules in hepatitis B virus therapy: can we provide any guidance?
inferred← citeshttps://doi.org/10.1002/advs.202304381openalex-snapshot
The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study
inferred← citeshttps://doi.org/10.1002/advs.202305204openalex-snapshot
Transcriptomic Signature of 3D Hierarchical Porous Chip Enriched Exosomes for Early Detection and Progression Monitoring of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/advs.202404274openalex-snapshot
Sensing of Liver‐Derived Nicotinamide by Intestinal Group 2 Innate Lymphoid Cells Links Liver Cirrhosis and Ulcerative Colitis Susceptibility
inferred← citeshttps://doi.org/10.1002/aid2.13190openalex-snapshot
Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: A preliminary finding
inferred← citeshttps://doi.org/10.1002/aid2.13276openalex-snapshot
The unsolved issues in oral antiviral therapy in HBeAg positive chronic hepatitis B patients
inferred← citeshttps://doi.org/10.1002/aid2.13356openalex-snapshot
The impact of early hepatitis B virus viral suppression on treatment response in entecavir‐treated hepatitis B e antigen‐positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/cam4.1468openalex-snapshot
RFX 1 participates in doxorubicin‐induced hepatitis B virus reactivation
inferred← citeshttps://doi.org/10.1002/cam4.3378openalex-snapshot
Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory‐wide cohort study
inferred← citeshttps://doi.org/10.1002/cam4.70185openalex-snapshot
Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg ‐negative hepatitis B virus‐related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis
inferred← citeshttps://doi.org/10.1002/ccr3.3896openalex-snapshot
Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: A case report
inferred← citeshttps://doi.org/10.1002/ccr3.5641openalex-snapshot
Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate
inferred← citeshttps://doi.org/10.1002/cld.1079openalex-snapshot
Viral Hepatitis in Pregnancy: An Update on Screening, Diagnosis, and Management
inferred← citeshttps://doi.org/10.1002/cld.1096openalex-snapshot
Prevention of Mother‐to‐Child Transmission of Hepatitis B Virus in the Western Pacific Region
inferred← citeshttps://doi.org/10.1002/cld.719openalex-snapshot
Hepatitis B: Standard and Novel Treatment Options
inferred← citeshttps://doi.org/10.1002/cld.757openalex-snapshot
Hepatology Clearance for Immunomodulation in Patients With Hepatitis B
inferred← citeshttps://doi.org/10.1002/cld.883openalex-snapshot
Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines
inferred← citeshttps://doi.org/10.1002/cld.893openalex-snapshot
CON: All Patients With Immune‐Tolerated Hepatitis B Virus Do Not Need to Be Treated
inferred← citeshttps://doi.org/10.1002/cld.950openalex-snapshot
Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen–Negative Patients: An Asian Perspective
inferred← citeshttps://doi.org/10.1002/cld.977openalex-snapshot
Affordability of Antiviral Therapy in Asia‐Pacific Countries and Its Impact on Public Health Outcomes
inferred← citeshttps://doi.org/10.1002/cpdd.1154openalex-snapshot
Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses
inferred← citeshttps://doi.org/10.1002/ctm2.137openalex-snapshot
Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single‐center, retrospective, propensity‐matched study
inferred← citeshttps://doi.org/10.1002/hep.29213openalex-snapshot
A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha
inferred← citeshttps://doi.org/10.1002/hep.29323openalex-snapshot
Hepatitis B cure: From discovery to regulatory approval
inferred← citeshttps://doi.org/10.1002/hep.29497openalex-snapshot
Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg‐negative chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.29690openalex-snapshot
Global microRNA expression profiling in the liver biopsies of hepatitis B virus–infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury
inferred← citeshttps://doi.org/10.1002/hep.29800openalex-snapshot
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
inferred← citeshttps://doi.org/10.1002/hep.29821openalex-snapshot
Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.29922openalex-snapshot
Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosis
inferred← citeshttps://doi.org/10.1002/hep.30050openalex-snapshot
Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study
inferred← citeshttps://doi.org/10.1002/hep.30082openalex-snapshot
Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog‐Treated or Untreated Patients During Chronic and Acute Infection
inferred← citeshttps://doi.org/10.1002/hep.30233openalex-snapshot
Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early‐Stage Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/hep.30474openalex-snapshot
The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review
inferred← citeshttps://doi.org/10.1002/hep.30788openalex-snapshot
Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg‐Positive Children With a Normal Alanine Aminotransferase Level
inferred← citeshttps://doi.org/10.1002/hep.30833openalex-snapshot
An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017
inferred← citeshttps://doi.org/10.1002/hep.30844openalex-snapshot
Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination
inferred← citeshttps://doi.org/10.1002/hep.31289openalex-snapshot
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection
inferred← citeshttps://doi.org/10.1002/hep.31525openalex-snapshot
Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg‐Negative Chronic Hepatitis B: To Retreat or Not to Retreat
inferred← citeshttps://doi.org/10.1002/hep.31554openalex-snapshot
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy
inferred← citeshttps://doi.org/10.1002/hep.31610openalex-snapshot
Comparison of Long‐Term Clinical Outcomes Between Spontaneous and Therapy‐Induced HBsAg Seroclearance
inferred← citeshttps://doi.org/10.1002/hep.31795openalex-snapshot
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.31890openalex-snapshot
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19
inferred← citeshttps://doi.org/10.1002/hep.32314openalex-snapshot
Getting to HBV cure: The promising paths forward
inferred← citeshttps://doi.org/10.1002/hep.32400openalex-snapshot
Changes in serum hepatitis B surface and e antigen, interferon‐inducible protein 10, and aminotransferase levels during combination therapy of immune‐tolerant chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep4.1014openalex-snapshot
Screening for hepatocellular carcinoma: What is missing?
inferred← citeshttps://doi.org/10.1002/hep4.1055openalex-snapshot
Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation
inferred← citeshttps://doi.org/10.1002/hep4.1112openalex-snapshot
Human immunodeficiency virus and liver disease: A comprehensive update
inferred← citeshttps://doi.org/10.1002/hep4.1118openalex-snapshot
HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations
inferred← citeshttps://doi.org/10.1002/hep4.1281openalex-snapshot
Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
inferred← citeshttps://doi.org/10.1002/hep4.1351openalex-snapshot
Maternal Immunity Influences Vertical Transmission of Hepatitis B to Newborns
inferred← citeshttps://doi.org/10.1002/hep4.1460openalex-snapshot
Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics
inferred← citeshttps://doi.org/10.1002/hep4.1520openalex-snapshot
HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination
inferred← citeshttps://doi.org/10.1002/hep4.1592openalex-snapshot
Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1002/hep4.1626openalex-snapshot
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB
inferred← citeshttps://doi.org/10.1002/hep4.1708openalex-snapshot
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep4.1859openalex-snapshot
Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis
inferred← citeshttps://doi.org/10.1002/hep4.1875openalex-snapshot
Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep4.2064openalex-snapshot
Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
inferred← citeshttps://doi.org/10.1002/iid3.1134openalex-snapshot
High immunocompetence in chronic hepatitis patients with normal alanine transaminase levels and and negative hepatitis B e‐antigen for the progression of liver fibrosis
inferred← citeshttps://doi.org/10.1002/iid3.793openalex-snapshot
Antibodies to Hepatitis B core antigen prevalence study in Kazakhstan
inferred← citeshttps://doi.org/10.1002/ila2.24openalex-snapshot
Significant histological changes are not rare in indeterminate‐phase chronic hepatitis B patients with hepatitis B e antigen‐negative and normal alanine aminotransferase levels
inferred← citeshttps://doi.org/10.1002/jbt.70521openalex-snapshot
Exosome Carrying OCT4/miR‐1246/β‐catenin Deriving From HBV Infected Hepatocytes Accelerated Liver Fibrosis
inferred← citeshttps://doi.org/10.1002/jcla.22341openalex-snapshot
Aspartate transaminase to platelet ratio index and gamma‐glutamyl transpeptidase‐to‐platelet ratio outweigh fibrosis index based on four factors and red cell distribution width‐platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jcla.23464openalex-snapshot
Studies on the serological markers for hepatitis B virus infection among type 2 diabetic patients
inferred← citeshttps://doi.org/10.1002/jcla.23640openalex-snapshot
Identification and external validation of the optimal FIB‐4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings
inferred← citeshttps://doi.org/10.1002/jcla.24990openalex-snapshot
Chinese expert consensus statement on the clinical application of AFP / AFP‐L3 %/ DCP using GALAD and GALAD ‐like algorithm in HCC
inferred← citeshttps://doi.org/10.1002/jgh3.12219openalex-snapshot
Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients
inferred← citeshttps://doi.org/10.1002/jgh3.12252openalex-snapshot
Screening for non‐alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter‐transient elastography
inferred← citeshttps://doi.org/10.1002/jgh3.12321openalex-snapshot
Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance
inferred← citeshttps://doi.org/10.1002/jgh3.13067openalex-snapshot
Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jgh3.70171openalex-snapshot
Seroprevalence and Risk Factors of Hepatitis B Virus Among Newly Diagnosed Cancer Patients in Khartoum State: Implications for Chemotherapy Management and Screening Protocols
inferred← citeshttps://doi.org/10.1002/jmv.24489openalex-snapshot
Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy
inferred← citeshttps://doi.org/10.1002/jmv.24620openalex-snapshot
Guillain–Barré syndrome following acute co‐super‐infection of hepatitis E virus and cytomegalovirus in a chronic hepatitis B virus carrier
inferred← citeshttps://doi.org/10.1002/jmv.24939openalex-snapshot
Hepatitis B among immigrants from Myanmar: Genotypes and their clinical relevance
inferred← citeshttps://doi.org/10.1002/jmv.24986openalex-snapshot
Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance
inferred← citeshttps://doi.org/10.1002/jmv.25364openalex-snapshot
Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near‐normal alanine aminotransferase
inferred← citeshttps://doi.org/10.1002/jmv.25377openalex-snapshot
HBcAg‐induced upregulated 4‐1BB ligand on B cells contributes to B‐cell hyperactivation during chronic hepatitis B infection
inferred← citeshttps://doi.org/10.1002/jmv.25435openalex-snapshot
Diagnostic thresholds and performance of noninvasive fibrosis scores are limited by age in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.25442openalex-snapshot
Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long‐term virological response to entecavir therapy: A randomized trial
inferred← citeshttps://doi.org/10.1002/jmv.25443openalex-snapshot
Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.25485openalex-snapshot
Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing
inferred← citeshttps://doi.org/10.1002/jmv.25515openalex-snapshot
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.25566openalex-snapshot
Efficacy and safety of telbivudine to prevent mother‐to‐child transmission of hepatitis B virus in middle‐ and late‐stage pregnancy with high viral loads
inferred← citeshttps://doi.org/10.1002/jmv.25628openalex-snapshot
Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.25950openalex-snapshot
Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long‐term observational cohort study
inferred← citeshttps://doi.org/10.1002/jmv.26011openalex-snapshot
The safety of antiviral therapy and drug withdrawal for the prevention of mother‐to‐child transmission of HBV during pregnancy
inferred← citeshttps://doi.org/10.1002/jmv.26916openalex-snapshot
Baseline serum exosome‐derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon
inferred← citeshttps://doi.org/10.1002/jmv.27761openalex-snapshot
Identification of potential plasma markers for hepatitis B virus‐related chronic hepatitis and liver fibrosis/cirrhosis
inferred← citeshttps://doi.org/10.1002/jmv.27779openalex-snapshot
Dose–response relationship between qAnti‐HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase based on liver biopsy
inferred← citeshttps://doi.org/10.1002/jmv.27863openalex-snapshot
Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
inferred← citeshttps://doi.org/10.1002/jmv.27877openalex-snapshot
Sofosbuvir‐based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study
inferred← citeshttps://doi.org/10.1002/jmv.28125openalex-snapshot
A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.28129openalex-snapshot
Decreased frequency of a novel T‐lymphocyte subset, CD3 + CD4 − CD7 + CD57 − T cells, in hepatitis B virus‐related end‐stage liver disease might contribute to disease progression
inferred← citeshttps://doi.org/10.1002/jmv.28210openalex-snapshot
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.28452openalex-snapshot
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis
inferred← citeshttps://doi.org/10.1002/jmv.28943openalex-snapshot
Development a novel nomogram model for predicting significant hepatic histological changes in chronic hepatitis B virus carriers
inferred← citeshttps://doi.org/10.1002/jmv.29142openalex-snapshot
IL‐21 collaborates with anti‐TIGIT to restore NK cell function in chronic HBV infection
inferred← citeshttps://doi.org/10.1002/jmv.29213openalex-snapshot
Higher HBeAg‐reversion virological relapse and lower sustained remission after treatment cessation in tenofovir‐treated HBeAg‐positive patients
inferred← citeshttps://doi.org/10.1002/jmv.29516openalex-snapshot
CXCL10 and its receptor in patients with chronic hepatitis B and their ability to predict HBeAg seroconversion during antiviral treatment with TDF
inferred← citeshttps://doi.org/10.1002/jmv.29863openalex-snapshot
A novel model based on serum N‐glycan markers for evaluating stage of liver necroinflammation in treatment‐naïve chronic hepatitis B patients
inferred← citeshttps://doi.org/10.1002/jmv.70021openalex-snapshot
HBV Antigen‐Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure
inferred← citeshttps://doi.org/10.1002/jmv.70350openalex-snapshot
HBcrAg Dynamic Change During Treatment Predicts HBsAg Loss in Pediatric Patients With Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.70939openalex-snapshot
Chronic Hepatitis B in Children Admitted to a Tertiary Hospital in Türkiye: A 23‐Year Observational Study
inferred← citeshttps://doi.org/10.1002/jmv.70946openalex-snapshot
Analysis of the Chronic Hepatitis B Care Cascade and Treatment Rates at a Tertiary Medical Center in Southern California
inferred← citeshttps://doi.org/10.1002/jum.14822openalex-snapshot
Dynamic Changes of the Aspartate Aminotransferase‐to‐Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment
inferred← citeshttps://doi.org/10.1002/kjm2.12114openalex-snapshot
Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
inferred← citeshttps://doi.org/10.1002/kjm2.12364openalex-snapshot
Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
inferred← citeshttps://doi.org/10.1002/kjm2.12413openalex-snapshot
Sorafenib use in hepatitis B virus‐ or hepatitis C virus‐related hepatocellular carcinoma: A propensity score matching study
inferred← citeshttps://doi.org/10.1002/kjm2.12518openalex-snapshot
Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation”
inferred← citeshttps://doi.org/10.1002/kjm2.12543openalex-snapshot
The compound annual growth rate of the fibrosis‐4 index in chronic hepatitis B patients
inferred← citeshttps://doi.org/10.1002/kjm2.12757openalex-snapshot
Well‐controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib
inferred← citeshttps://doi.org/10.1002/kjm2.12771openalex-snapshot
Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs
inferred← citeshttps://doi.org/10.1002/kjm2.70290openalex-snapshot
Machine Learning Model for Predicting Hepatocellular Carcinoma Development in Patients With Hepatitis B Virus‐Related Cirrhosis Receiving Antiviral Therapy
inferred← citeshttps://doi.org/10.1002/med.21490openalex-snapshot
2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants
inferred← citeshttps://doi.org/10.1002/pd.5452openalex-snapshot
Mother‐to‐child transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study
inferred← citeshttps://doi.org/10.1002/ped4.12205openalex-snapshot
Prevention strategies of mother‐to‐child transmission of hepatitis B virus (HBV) infection
inferred← citeshttps://doi.org/10.1002/phar.2340openalex-snapshot
Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies
inferred← citeshttps://doi.org/10.1002/phar.2508openalex-snapshot
Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab
inferred← citeshttps://doi.org/10.1002/poh2.70037openalex-snapshot
The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis
inferred← citeshttps://doi.org/10.1002/psp4.70164openalex-snapshot
A Systematic Review and Model‐Based Meta‐Analysis of Pegylated‐Interferon‐α‐Induced HBsAg Loss in Chronic Hepatitis B Virus Infection
inferred← citeshttps://doi.org/10.1002/rmv.2051openalex-snapshot
Pregenomic RNA: How to assist the management of chronic hepatitis B?
inferred← citeshttps://doi.org/10.1002/rmv.2182openalex-snapshot
Primer and probe conservation issue in the quantification of hepatitis B virus DNA
inferred← citeshttps://doi.org/10.1002/rmv.2216openalex-snapshot
Tenofovir disoproxil fumarate for prevention of mother‐to‐child transmission of hepatitis B virus: A systematic review and meta‐analysis of randomised control trials
inferred← citeshttps://doi.org/10.1002/ueg2.12176openalex-snapshot
Clinical management of chronic hepatitis B: A concise overview
inferred← citeshttps://doi.org/10.1002/ueg2.12494openalex-snapshot
Management of chronic HBV‐HDV patients chronic HBV‐HDV infection: A review on new management options
inferred← citeshttps://doi.org/10.1002/ueg2.12564openalex-snapshot
A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development
inferred← citeshttps://doi.org/10.1002/ygh2.393openalex-snapshot
Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy
inferred← citeshttps://doi.org/10.1002/ygh2.471openalex-snapshot
Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1007/978-1-4939-9544-8_32-1openalex-snapshot
Hepatitis Viruses: Hepatitis B and Hepatitis D
inferred← citeshttps://doi.org/10.1007/978-1-4939-9544-8_32-2openalex-snapshot
Hepatitis Viruses: Hepatitis B and Hepatitis D
inferred← citeshttps://doi.org/10.1007/978-1-4939-9544-8_32-3openalex-snapshot
Hepatitis Viruses: Hepatitis B and Hepatitis D
inferred← citeshttps://doi.org/10.1007/978-3-030-03535-8_1openalex-snapshot
Global Epidemiology of Acute Viral Hepatitis A–E
inferred← citeshttps://doi.org/10.1007/978-3-030-03757-4_6openalex-snapshot
Treatment of Hepatitis C Virus in Special Populations (HBV Coinfection, Drug Users, and Prisoners)
inferred← citeshttps://doi.org/10.1007/978-3-030-50983-5_9openalex-snapshot
Viral Hepatitis B, C and D in ALF and ALF/CLD
inferred← citeshttps://doi.org/10.1007/978-3-030-83434-0_44openalex-snapshot
Congenital Infection 1 (Syphilis, AIDS, and Viral Hepatitis)
inferred← citeshttps://doi.org/10.1007/978-3-031-52641-1_54-1openalex-snapshot
ApoE and Liver Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-69800-2_30openalex-snapshot
Interactions of Drugs for Liver Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-90225-3_1openalex-snapshot
Should All Patients with Hepatitis B Virus Undergo Hepatocellular Carcinoma Surveillance?
inferred← citeshttps://doi.org/10.1007/978-3-319-34214-6_27openalex-snapshot
Clinical Features and Clinician’s Diagnostic Approach to Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-319-93449-5_7openalex-snapshot
Current Management of Chronic HBV Infection
inferred← citeshttps://doi.org/10.1007/978-3-319-95828-6_3openalex-snapshot
Histopathology of Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/978-94-024-1603-9_5openalex-snapshot
Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure)
inferred← citeshttps://doi.org/10.1007/978-94-024-1606-0_1openalex-snapshot
Introduction to Acute Exacerbation of Chronic Hepatitis B (AECHB)
inferred← citeshttps://doi.org/10.1007/978-94-024-1606-0_5openalex-snapshot
Immunological Features of AECHB
inferred← citeshttps://doi.org/10.1007/978-981-10-4843-2_10openalex-snapshot
Chronic HBV Infection: Interferon Therapy and Long-Term Outcomes
inferred← citeshttps://doi.org/10.1007/978-981-10-4843-2_11openalex-snapshot
Nucleos(t)ide Therapy and Long-Term Outcomes
inferred← citeshttps://doi.org/10.1007/978-981-10-4843-2_13openalex-snapshot
Treatment of HCV, HDV, or HIV Coinfection
inferred← citeshttps://doi.org/10.1007/978-981-10-4843-2_14openalex-snapshot
Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women
inferred← citeshttps://doi.org/10.1007/978-981-10-4843-2_16openalex-snapshot
Hepatitis B Virus Reactivation and Management of Patients Undergoing Immunosuppression
inferred← citeshttps://doi.org/10.1007/978-981-13-0050-9_4openalex-snapshot
Mother-to-Infant Transmission of Viral Hepatitis
inferred← citeshttps://doi.org/10.1007/978-981-13-9151-4_2openalex-snapshot
HBV Genome and Life Cycle
inferred← citeshttps://doi.org/10.1007/978-981-13-9151-4_6openalex-snapshot
Present and Future Therapies for Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_10openalex-snapshot
Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_12openalex-snapshot
Chronic Hepatitis B Virus Infection: Interferon Therapy and Long-Term Outcomes
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_13openalex-snapshot
Nucleos(t)ide Therapy and Long-Term Outcomes
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_15openalex-snapshot
Treatment of HCV, HDV, or HIV Coinfections
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_16openalex-snapshot
Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_18openalex-snapshot
Hepatitis B Virus Reactivation and Management of Patients Undergoing Immunosuppression
inferred← citeshttps://doi.org/10.1007/978-981-16-3615-8_19openalex-snapshot
Novel Therapy for Functional Cure of Chronic Hepatitis B Virus Infection
inferred← citeshttps://doi.org/10.1007/978-981-19-2615-0_1openalex-snapshot
Anti-HBV Drugs in Liver Cirrhosis
inferred← citeshttps://doi.org/10.1007/978-981-96-7364-3_16openalex-snapshot
ALPPS vs Traditional Two-Stage Hepatectomy
inferred← citeshttps://doi.org/10.1007/978-981-99-9195-2_16openalex-snapshot
Path to Cure Hepatitis B: How Far Are We?
inferred← citeshttps://doi.org/10.1007/s00198-026-08135-xopenalex-snapshot
Clinical insights into the association between chronic liver disease and osteoporosis
inferred← citeshttps://doi.org/10.1007/s00216-026-06338-zopenalex-snapshot
Development of a hypersensitive digital ELISA system for hepatitis B core antigen
inferred← citeshttps://doi.org/10.1007/s00228-018-2487-4openalex-snapshot
Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00277-025-06210-7openalex-snapshot
Combining immunosuppressive therapy with low dosage eltrombopag in Chinese patients with severe aplastic anemia: mild aggravation of hepatic injury
inferred← citeshttps://doi.org/10.1007/s00296-019-04437-yopenalex-snapshot
Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapy
inferred← citeshttps://doi.org/10.1007/s00296-022-05169-2openalex-snapshot
Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study
showing the first 200 of 2539 · page through all 2539
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.